title: Adverse effects of aspirin in the treatment of asymptomatic carotid artery stenosis. The VA Cooperative Asymptomatic Carotid Artery Stenosis Study Group.
abstract: We prospectively analyzed adverse effects of aspirin in a multicentered cooperative study undertaken to determine the role of endarterectomy in the treatment of asymptomatic carotid artery stenosis. Persons with active peptic ulcer disease or known intolerance to aspirin were excluded from the study. Patients initially received 650 mg aspirin twice daily. After a 54-month recruitment period, 444 patients in 11 centers were followed up for as many as 8 years (mean 47.9 +/- 27.9 months). Patients intolerant to 650 mg aspirin twice daily could be switched to enteric-coated aspirin or "low-dose" aspirin (80 to 325 mg daily). At the conclusion of the study, we performed a cross-sectional analysis of aspirin usage and complications. Overall, there were 757 episodes reported wherein adjustments in study medications were made, including cessation and change in formulation or dosage. At the conclusion of the study, at the time of death, or at occurrence of a neurologic end point, 16% of patients were off medication entirely, 51% had been converted to enteric-coated aspirin, and only 33% were taking regular aspirin with 27% of those having been placed on a reduced dosage. Adverse reactions were ascertained from 4954 patient visit records. In all there were a total of 837 adverse reactions reported, or one in every 5.9 visits. The most frequently reported reaction was heartburn or stomach pain for which 372 episodes were reported in 184 (42%) patients. Nausea or vomiting occurred on 79 occasions in 58 patients, and bloody stools were reported 52 times in 41 patients. We conclude that high-dose aspirin therapy for asymptomatic carotid artery stenosis is poorly tolerated and that adverse reactions even to low-dose enteric-coated aspirin are common even in patients screened for aspirin intolerance.
authors.affiliation: VA Cooperative Studies Program Coordinating Center (CSPCC), Perry Point, Md.
authors.forename: W C
authors.initials: WC
authors.lastname: Krupski
authors.forename: D G
authors.initials: DG
authors.lastname: Weiss
authors.forename: J H
authors.initials: JH
authors.lastname: Rapp
authors.forename: J D
authors.initials: JD
authors.lastname: Corson
authors.forename: R W
authors.initials: RW
authors.lastname: Hobson
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016893:Carotid Stenosis / Q000188:drug therapy* / Q000601:surgery; D016009:Chi-Square Distribution; D003131:Combined Modality Therapy; D016894:Endarterectomy, Carotid; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D013608:Tablets, Enteric-Coated
chemical_list: D013608:Tablets, Enteric-Coated; D001241:Aspirin